List of Excipients in Branded Drug EPOPROSTENOL

Generic Drugs Containing EPOPROSTENOL

Company	Ingredient	NDC	Excipient
Sun Pharmaceutical Industries Inc	epoprostenol	62756-059	GLYCINE
Sun Pharmaceutical Industries Inc	epoprostenol	62756-059	SODIUM HYDROXIDE
Sun Pharmaceutical Industries Inc	epoprostenol	62756-059	SUCROSE
Mylan Institutional LLC	epoprostenol	67457-587	ARGININE
Mylan Institutional LLC	epoprostenol	67457-587	SODIUM HYDROXIDE
Mylan Institutional LLC	epoprostenol	67457-587	SUCROSE
Gland Pharma Limited	epoprostenol	68083-707	GLYCINE

What are the Most Frequently-Used Excipients in EPOPROSTENOL?

# Of NDCs	Excipient
1	ARGININE
2	GLYCINE
3	SODIUM HYDROXIDE
3	SUCROSE

Epoprostenol Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Epoprostenol has a mature active pharmaceutical ingredient and limited core-patent protection, but its formulation remains commercially sensitive because the drug is chemically unstable, continuously infused, highly alkaline after reconstitution, and dependent on strict handling conditions. The strongest excipient opportunities are in stability enhancement, ready-to-use presentations, container-closure systems, low-sorption materials, and differentiated hospital workflow products.

What excipients are used in approved epoprostenol products?

Approved epoprostenol products generally use a small excipient system built around glycine, mannitol, sodium hydroxide, and, in some products, L-arginine.

Product	Sponsor	FDA application	Principal excipients	Presentation
Flolan	GlaxoSmithKline historically; current authorized distributors vary by market	NDA 019798	Glycine, mannitol, sodium hydroxide	Lyophilized powder for continuous IV infusion
Veletri	Actelion Pharmaceuticals, a Janssen company	NDA 022260	Glycine, mannitol, L-arginine, sodium hydroxide	Lyophilized powder for continuous IV infusion
Generic epoprostenol sodium products	Multiple generic manufacturers	ANDA products	Typically glycine, mannitol, sodium hydroxide; composition varies by manufacturer	Lyophilized powder for injection

Flolan and Veletri are not interchangeable from a handling perspective. Their reconstitution instructions, stability periods, diluents, storage conditions, and concentration ranges must be evaluated product by product. FDA labeling identifies glycine and mannitol as major formulation components and sodium hydroxide as a pH-adjusting agent. Veletri includes L-arginine in its formulation, which supports a differentiated stabilization and buffering approach.[1-3]

Why glycine is used in epoprostenol formulations

Glycine functions as a bulking agent and stabilizing excipient in the lyophilized cake. It can improve cake structure, support reconstitution, and reduce formulation stress during freeze-drying.

Glycine is also compatible with the highly alkaline formulation environment used to improve epoprostenol stability. Its use is established in approved products, which reduces regulatory risk for generic and lifecycle-development programs.

Why mannitol is used

Mannitol is primarily a bulking and cake-forming agent. It can improve the physical structure of the lyophilized product and support consistent vial fill and reconstitution.

Mannitol crystallization must be controlled during lyophilization. Variations in polymorphic state, residual moisture, and cake morphology can affect reconstitution time, appearance, and long-term stability. A formulation using mannitol requires process control over freezing, annealing, primary drying, and secondary drying.

Why sodium hydroxide is used

Epoprostenol is more stable at alkaline pH than at neutral pH. Sodium hydroxide is used to adjust the formulation to a strongly alkaline range, generally around pH 11.7 to 12.3 in labeled products.[1-3]

The high pH creates product-development constraints:

• Compatibility with elastomers, tubing, syringes, and infusion reservoirs must be demonstrated.
• Adsorption and extractables can change with pH.
• Patient-contact materials must be screened for chemical resistance.
• Diluent selection affects final pH and stability.
• Accidental extravasation and local tolerability require clinical handling controls.

Why Veletri includes L-arginine

Veletri uses L-arginine with glycine and mannitol. L-arginine can contribute to pH control, ionic strength, and stabilization of the formulation. It also gives the product a formulation profile that differs from the traditional glycine-mannitol system.

For generic manufacturers, matching a Veletri-type excipient system may improve formulation comparability but can increase analytical and manufacturing complexity. The applicant must show that the product meets applicable requirements for identity, strength, quality, purity, sterility, particulate matter, reconstitution, and stability.

What formulation problems create commercial opportunities for epoprostenol?

The main commercial problem is that epoprostenol has a short effective stability window after preparation compared with many modern injectable therapies. Patients with pulmonary arterial hypertension receive continuous infusion, so product interruption can cause rapid clinical deterioration. The commercial value of excipient innovation therefore depends on operational reliability, not only on longer shelf life.

Stability after reconstitution

Epoprostenol products are supplied as sterile lyophilized powders. After reconstitution and dilution, the solution has limited stability that depends on:

• Temperature
• Concentration
• Diluent
• Container material
• Infusion device
• Storage duration
• Light exposure
• Microbiological controls

Veletri was developed partly around improved stability and room-temperature handling relative to older epoprostenol presentations. This created a product-level advantage in home infusion and emergency replacement scenarios.[2]

A formulation that provides longer in-use stability without changing the active concentration could support premium pricing, hospital formulary preference, and lower pharmacy compounding burden.

Continuous infusion and device compatibility

Epoprostenol is delivered through ambulatory infusion systems. The formulation therefore interacts with:

• Polyvinyl chloride and polyolefin tubing
• Syringe reservoirs
• Cassette reservoirs
• Infusion pump components
• Filters
• Connectors
• Elastomeric seals
• Low-volume dead spaces

A formulation can meet conventional stability specifications while still producing unacceptable adsorption, precipitation, particulate formation, or concentration loss in a particular delivery system. Excipient selection and container-closure design should be developed together rather than separately.

Alkalinity and material compatibility

The strongly alkaline formulation limits the choice of primary and secondary packaging materials. Commercial opportunities exist for prequalified systems that combine:

• Low-sorption tubing
• Alkaline-resistant elastomers
• Validated syringe materials
• Compatible cassette reservoirs
• Low-extractables connectors
• Integrated labeling for storage and replacement timing

The highest-value product may therefore be a drug-device package rather than a new excipient alone.

What excipient strategies could differentiate an epoprostenol product?

Strategy 1: Optimize the established glycine-mannitol system

The lowest-risk path is to retain the established glycine-mannitol formulation while optimizing:

• Excipient concentration
• Residual moisture
• Cake porosity
• Reconstitution speed
• Vial headspace
• Stopper compatibility
• Thermal stability
• Dilution instructions

This approach is appropriate for a generic or hospital-focused product because it uses familiar excipients and limits toxicological risk.

The commercial advantage would come from manufacturing efficiency, lower reject rates, faster reconstitution, or improved compatibility rather than a novel chemical composition.

Strategy 2: Use an arginine-containing formulation

An L-arginine-containing formulation can support a Veletri-like stability profile and provide a differentiated product design. The main development issues are:

• Control of pH and ionic strength
• Impact on freeze-drying behavior
• Reconstitution performance
• Compatibility with infusion materials
• Comparability against reference products
• Potential changes in osmolality and injection-site tolerability

This strategy is more attractive for a branded lifecycle product than for a conventional ANDA, where unnecessary excipient differences can complicate the development package.

Strategy 3: Develop a ready-to-use liquid

A ready-to-use epoprostenol solution could eliminate bedside reconstitution and reduce pharmacy preparation time. The technical barrier is chemical stability. The product would need to maintain potency and impurity limits during:

• Long-term storage
• Shipping
• Temperature excursions
• In-use infusion
• Repeated handling
• Contact with the delivery system

A ready-to-use product would likely require a combination of alkaline pH control, oxygen management, low-permeability packaging, light protection, and validated low-sorption materials.

Possible packaging formats include:

• Prefilled syringes
• Single-use infusion cassettes
• Pharmacy-prepared bags
• Dual-chamber systems
• Cartridge-based ambulatory pumps

The commercial opportunity is substantial because ready-to-use delivery addresses a direct hospital and home-care workflow problem. The technical and regulatory burden is materially higher than for a lyophilized vial.

Strategy 4: Extend in-use stability

An in-use stability extension could be more commercially achievable than a new ready-to-use liquid. The product would remain lyophilized but allow a longer period after reconstitution or dilution.

Potential approaches include:

• Improved pH control
• Reduced oxygen exposure
• Lower-sorption packaging
• Chelator screening
• Antioxidant screening
• Optimized ionic strength
• Better protection from light
• Higher-concentration presentations that reduce reservoir volume

Any antioxidant or chelator would require careful assessment because epoprostenol is administered continuously to critically ill patients. New excipients would increase safety, extractables, compatibility, and regulatory requirements.

What formulations are protected by epoprostenol patents?

The original epoprostenol composition-of-matter and use patents are generally old and have expired or are no longer the main commercial barrier in the United States. Current protection is more likely to arise from formulation, manufacturing, container-closure, delivery-device, or method-of-use claims.

Protection category	Commercial relevance	Relative strength
Epoprostenol active ingredient	Core molecule and primary therapeutic use	Low because of age and expiration
Glycine-mannitol lyophilized formulation	Supports generic product development	Low to moderate, depending on claim scope
Arginine-containing formulation	May distinguish stability and handling characteristics	Moderate if supported by unexpected stability data
Ready-to-use liquid formulation	Could protect a differentiated presentation	Moderate to high if claims cover a narrow, non-obvious stability solution
Infusion cassette or container system	Addresses device compatibility and workflow	Moderate
Reconstitution and dilution method	Can support instructions-for-use protection	Low to moderate
Pulmonary arterial hypertension method of use	May cover selected patient populations or dosing regimens	Usually limited by prior art
Manufacturing process	Can protect lyophilization and impurity control	Moderate if process-specific and difficult to design around

A formulation patent is stronger when it links a defined excipient range to a measurable technical result, such as a specified impurity profile, stability period, reconstitution time, or concentration retention in a named container system. Broad claims covering conventional glycine, mannitol, sodium hydroxide, or arginine combinations face substantial obviousness and prior-art exposure.

What is the Orange Book status of epoprostenol?

FDA-approved epoprostenol products are listed as drug products rather than biologics. They are eligible for abbreviated generic competition through the ANDA pathway, subject to the applicable reference-product and labeling requirements.

The Orange Book should be reviewed by application number and product name for current patents, exclusivity, and therapeutic-equivalence listings. Flolan and Veletri have mature regulatory histories, and their original statutory exclusivity periods have expired. Any remaining commercial patent risk depends on currently listed patents and the scope of later-issued formulation or device claims.[4]

Epoprostenol has no conventional biosimilar pathway risk. It is a small-molecule drug, not a therapeutic protein or other biologic subject to section 351(k) biosimilar approval.

When does epoprostenol lose exclusivity?

The principal loss of exclusivity occurred years ago because epoprostenol was first approved in the 1990s. Current competition is driven by generic injectable products, manufacturing reliability, hospital contracting, and product-specific stability claims rather than by basic molecule exclusivity.

Milestone	Approximate timing or status
First U.S. approval of Flolan	1995
Original small-molecule exclusivity	Expired
Original composition and use patent estate	Largely expired
Veletri U.S. approval	2008
Current market access	Brand and generic injectable products
Biosimilar pathway	Not applicable
Main remaining barriers	Sterile manufacturing, stability, device compatibility, supply reliability

A generic applicant may still face regulatory or commercial barriers even when core patents have expired. These include complex injectable manufacturing, limited clinical-use experience with the product, hospital substitution policies, and the need to demonstrate reliable preparation and administration.

How do Paragraph IV challenges affect epoprostenol?

Paragraph IV litigation is less likely to center on the active ingredient because the molecule and original patents are old. A challenge would more likely target:

• Later-listed formulation patents
• Stability claims
• Reconstitution methods
• Container or infusion-system claims
• Method-of-use patents
• Product-by-process claims

For a generic applicant, the key legal question is whether the proposed formulation can avoid infringement while maintaining pharmaceutical equivalence and label consistency. A formulation that is materially different from the reference product may reduce patent risk but increase regulatory complexity.

The commercial value of a Paragraph IV strategy is also constrained by the relatively specialized market. A successful challenge would need to justify litigation expense against the addressable volume of pulmonary arterial hypertension and critical-care use.

Which companies are challenging epoprostenol products?

The competitive field includes originator and authorized-generic channels associated with GlaxoSmithKline, Actelion/Janssen, and manufacturers of generic epoprostenol sodium for injection. Public regulatory records identify multiple approved or marketed products, but the commercial market is fragmented by country, supplier, product concentration, and distribution channel.

The relevant competitive variables are:

• FDA approval status
• Therapeutic-equivalence rating
• Availability of 0.5 mg and 1.5 mg vials
• Reconstitution and dilution instructions
• Room-temperature stability
• Hospital contract pricing
• Supply continuity
• Compatibility with infusion pumps
• Pharmacy and home-infusion support

A low-price generic is not automatically a complete substitute if its stability period, diluent instructions, or device compatibility differs from the incumbent product.

What manufacturing and IP barriers exist for epoprostenol?

Sterile lyophilization

Epoprostenol is a high-value sterile injectable with a narrow tolerance for contamination, potency loss, and particulate formation. The lyophilization cycle must control:

• Fill-volume uniformity
• Freezing behavior
• Primary drying endpoint
• Secondary drying temperature
• Residual moisture
• Cake collapse
• Reconstitution time
• Vial-to-vial variability

Manufacturing know-how may provide a stronger practical barrier than an expired composition patent.

Impurity control

Epoprostenol degradation can generate related substances during manufacture, storage, reconstitution, and infusion. A robust analytical package should monitor:

• Assay
• Degradation products
• Related substances
• pH
• Appearance
• Particulates
• Sterility
• Bacterial endotoxins
• Container-closure integrity

The impurity profile can differ between a glycine-mannitol formulation and an arginine-containing formulation. Stability-indicating methods should be developed before excipient selection is finalized.

Container-closure integrity

Vials, stoppers, syringes, cassettes, and tubing must be assessed under the final alkaline formulation conditions. Extractables and leachables can become a significant development issue, especially for ready-to-use presentations and long-duration infusion.

A supplier that can offer a validated formulation-container-device combination has a stronger commercial position than a supplier selling an excipient blend alone.

How strong is the epoprostenol patent estate?

The patent estate is weak for the basic active ingredient and stronger only in narrow technical areas.

A practical scoring framework is:

Asset type	Estimated strategic value
Original epoprostenol molecule patents	Low
Broad conventional excipient claims	Low
Defined stability-enhancing formulation	Moderate
Ready-to-use liquid with long in-use stability	Moderate to high
Device-specific delivery system	Moderate
Manufacturing process with demonstrated impurity control	Moderate
Narrow method-of-use claim	Low to moderate

Patent strength depends on claim construction, prosecution history, written description, enablement, prior art, and the exact marketed product. Commercial exclusivity is more likely to arise from a complete product system, including formulation, packaging, device, instructions, and manufacturing know-how.

What are the best commercial opportunities in epoprostenol excipients?

The highest-probability opportunities are:

1. A qualified glycine-mannitol excipient platform for generic lyophilized products.
2. A formulation and container package that extends post-reconstitution stability.
3. Low-sorption, alkaline-compatible infusion components.
4. Ready-to-use or pharmacy-ready infusion cassettes.
5. Contract development and manufacturing services for sterile lyophilized epoprostenol.
6. Analytical packages for degradation, extractables, and container compatibility.
7. Excipient and packaging systems validated for home infusion.

The strongest near-term business case is likely a combination of established excipients with improved packaging and handling. A novel excipient would carry higher regulatory risk without necessarily producing a proportionate commercial benefit.

How does epoprostenol compare with treprostinil?

Treprostinil has a broader range of delivery options, including subcutaneous, intravenous, inhaled, and oral formulations in some markets. Epoprostenol remains clinically important because of its established role in severe pulmonary arterial hypertension and critical-care use, but its continuous-infusion logistics create a larger formulation burden.

Attribute	Epoprostenol	Treprostinil
Chemical stability	Relatively challenging	Generally more forgiving
Main delivery burden	Continuous IV infusion and frequent solution handling	Multiple delivery routes
Excipient opportunity	Stability, packaging, infusion compatibility	Route-specific tolerability and release control
Ready-to-use potential	High commercial value but technically difficult	Already more feasible across dosage forms
Biosimilar risk	None	None
Generic competition	Established injectable competition	Broader route-specific competition

Epoprostenol provides a clearer commercial rationale for stability and device innovation because treatment interruption and preparation errors carry significant operational consequences.

Key Takeaways

• Epoprostenol uses a compact excipient system centered on glycine, mannitol, sodium hydroxide, and, in Veletri, L-arginine.
• The main formulation problem is limited stability during reconstitution, dilution, storage, and continuous infusion.
• Core molecule and original-use patent protection are largely exhausted.
• Remaining IP value is concentrated in defined stability formulations, container-closure systems, infusion devices, and manufacturing processes.
• Epoprostenol has no biosimilar pathway because it is a small-molecule drug.
• Ready-to-use liquids and infusion cassettes offer the largest commercial upside but require substantial stability and compatibility work.
• The lowest-risk opportunity is an established-excipient formulation combined with better lyophilization, packaging, and infusion-system performance.
• Manufacturing reliability, sterile capacity, and hospital supply continuity may be more important competitive barriers than broad patent protection.

FAQs About Epoprostenol Excipient and Formulation Strategy

Can epoprostenol be formulated without mannitol?

Yes, but removing mannitol would alter cake structure, solids content, reconstitution behavior, and potentially stability. A replacement bulking agent would require full formulation and lyophilization development.

Is L-arginine required in every epoprostenol product?

No. L-arginine is present in Veletri but is not universal across epoprostenol formulations. Product-specific labeling controls the excipient composition and handling requirements.

Can epoprostenol be supplied as a prefilled syringe?

Potentially, but the product would require long-term liquid stability, alkaline-compatible materials, container-closure integrity, sterility assurance, and validated compatibility with the intended infusion pump.

Which excipient is most important for epoprostenol stability?

The pH-adjustment system is central because epoprostenol stability depends strongly on an alkaline environment. Glycine, mannitol, and arginine also affect the solid-state and reconstituted formulation properties.

Is epoprostenol an attractive target for a new excipient?

Usually not as a stand-alone excipient opportunity. The stronger commercial model is a validated formulation-platform or drug-device package that improves stability, reduces preparation steps, and supports continuous home or hospital infusion.

References

1. U.S. Food and Drug Administration. (2023). Flolan (epoprostenol sodium) for injection: Prescribing information.
2. U.S. Food and Drug Administration. (2023). Veletri (epoprostenol sodium) for injection: Prescribing information.
3. U.S. National Library of Medicine. (2024). DailyMed: Epoprostenol sodium injection product labeling.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.